Boehringer Ingelheim participates in Second Middle East Animal Health Exhibition
United Arab Emirates, Dubai – 6th February, 2018:, Boehringer Ingelheim Animal Health, the second largest animal health company in the world, participated in the 2018 International Trade Show ‘From Feed to Food for the Middle East and Africa’, which took place in Abu Dhabi recently. Over 8000 visitors and 300 participants attended the second edition of the event to discuss the latest trends and findings around Animal Feed to Food solutions and technological advancement within the industry.
The event brought together leading experts in Animal Health from the region to highlight the latest innovative as well as medical solutions for production animals.
Boehringer Ingelheim Animal Health held a session with a focus on avian and cattle, and the different preventive solutions the company provides. The avian and cattle segments continue to grow due to an increased demand, particularly in the Middle East and Africa region (MEA).
Enrique Manzoni, Managing Director of Boehringer Ingelheim Middle East, Turkey and Africa (META) said, “Animal Health is an important topic that directly links to our daily lives and nutrition. In large parts of the world, including our region, avian and cattle will remain the fastest growing source of animal protein. To that extent, preventive vaccination is one approach to controlling any diseases. We have applied a lot of advances in this area and our commitment is to support in the investment of a healthier animal ecosystem, which in return would reflect in healthier communities.”
“When animals are healthy, humans are healthy too. Boehringer Ingelheim works to provide sustainable animal health solutions including vaccines with proven effectiveness and safety that accommodates the region’s specific needs. As known leaders and innovators in this field, Boehringer Ingelheim is frequently consulted for assistance in identifying new diseases and formulating new therapies or new diagnostic techniques to control diseases. We will continue to seek methods to further research and develop ground-breaking solutions for the animal health industry in line with the company’s business objectives.’’ added Enrique.
Boehringer Ingelheim works with advanced products, not only to reduce disease and encourage wellness in animals, but also to build the reputation and enhance the quality of care delivered by veterinarians.
Earlier last year, Boehringer Ingelheim finalized its swap transaction to acquire Merial, a business which was valued at €11.4 bn, following a positive year for the animal health business. The Boehringer Ingelheim animal health business is now the second largest company in the global animal health market, and is the top provider worldwide of parasiticides and vaccines for pets, companion animals and production animals. The combined company is now the global leader in the pets, equine and veterinary public health categories, with a strong position in avian and cattle.
Across the Middle East, Turkey and Africa (META) region, Boehringer Ingelheim provides solutions that improve health in both companion animals that includes pets and equines, and production animals that includes avian, ruminants and VPH. With innovative biological, pharmaceutical and nutraceutical products, based on its own research and development network, and industry-leading technical service veterinarians, the company is focused on serving the needs of its customers and its animal patients in the region.
-END-
About Boehringer Ingelheim
Innovative medicines for people and animals have for more than 130 years been what the research-driven pharmaceutical company Boehringer Ingelheim stands for. Boehringer Ingelheim is one of the industry’s top 20 pharmaceutical companies and to this day remains family-owned. Day by day, some 50,000 employees create value through innovation for the three business areas human pharmaceuticals, animal health and biopharmaceutical contract manufacturing. In 2016, Boehringer Ingelheim achieved net sales of around 15.9 billion euros. With more than three billion euros, R&D expenditure corresponds to 19.6 per cent of net sales.
Social responsibility comes naturally to Boehringer Ingelheim. That is why the company is involved in social projects, such as the “Making More Health” initiative. Boehringer Ingelheim also actively promotes workforce diversity and benefits from its employees’ different experiences and skills. Furthermore, the focus is on environmental protection and sustainability in everything the company does.
More information about Boehringer Ingelheim can be found on www.boehringer-ingelheim.com or in our annual report: http://annualreport.boehringer-ingelheim.com
About Boehringer Ingelheim Animal Health
As the second largest animal health business in the world, Boehringer Ingelheim is committed to improving animal health. With more than 10,000 employees worldwide, Boehringer Ingelheim Animal Health has products available in more than 150 markets and a global presence in 99 countries. For more information about Boehringer Ingelheim Animal Health, click here.
For more information, please contact:
Sara Shamel
Head of External Communication | META
Boehringer Ingelheim
Sara.Shamel@boehringer-ingelheim.com